HOPE Biobank for bone marrow failure patients
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study collects blood samples from patients with aplastic anemia, sickle cell disease, thalassemia, or other bone marrow failure conditions who are receiving a stem cell transplant or gene therapy. The samples will be stored and used for future research to better understand and treat these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have aplastic anemia, sickle cell disease, thalassemia, or another type of bone marrow failure that is not cancer.
- You are going to have a stem cell transplant or gene therapy for your condition.
- You weigh at least 22 pounds (10 kilograms) at the time you join the study.
- You agree to let the research team link your study data with your medical records from the transplant registry.
- If you are a related donor for an eligible patient, you can also join this study. The patient can still join even if you decide not to.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if removing a type of immune cell from a donor's stem cell graft can prevent graft-versus-host disease (GVHD) in children with certain non-cancer blood or immune disorders. It aims to make the transplant safer by reducing the risk of the donor cells attacking the child's body.
This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial is a registry that follows children and young adults up to age 26 who are having a bone marrow transplant, to better understand complications related to blood vessel and organ injury. It may help future patients by improving how doctors predict and prevent these problems.
Hear when a new Hemoglobinopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.